AZD-4721
- Generic Name
- AZD-4721
A Study to Evaluate RIST4721 in Familial Mediterranean Fever (FMF)
- First Posted Date
- 2022-07-07
- Last Posted Date
- 2023-02-13
- Lead Sponsor
- Aristea Therapeutics, Inc.
- Registration Number
- NCT05448391
A Study to Evaluate RIST4721 in Hidradenitis Suppurativa (HS)
- First Posted Date
- 2022-04-27
- Last Posted Date
- 2023-06-13
- Lead Sponsor
- Aristea Therapeutics, Inc.
- Target Recruit Count
- 25
- Registration Number
- NCT05348681
- Locations
- πΊπΈ
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
πΊπΈFlorida Academic Centers Research and Education, LLC, Coral Gables, Florida, United States
πΊπΈUSC IDS Pharmacy, Los Angeles, California, United States
A Phase 2b Study to Evaluate RIST4721 in Palmoplantar Pustulosis (PPP)
- First Posted Date
- 2022-01-18
- Last Posted Date
- 2023-06-29
- Lead Sponsor
- Aristea Therapeutics, Inc.
- Target Recruit Count
- 79
- Registration Number
- NCT05194839
- Locations
- πΊπΈ
Clinical Science Institute, Santa Monica, California, United States
πΊπΈEncore Medical Research, LLC, Hollywood, Florida, United States
πΊπΈAventiv Research Inc., Dublin, Ohio, United States
A Study to Investigate the Effects of RIST4721 on the Inflammatory Response in Healthy Male Subjects Using a Blister Model
- First Posted Date
- 2019-09-26
- Last Posted Date
- 2020-06-29
- Lead Sponsor
- Aristea Therapeutics, Inc.
- Target Recruit Count
- 32
- Registration Number
- NCT04105959
- Locations
- π¬π§
MAC Clinical Research, Manchester, United Kingdom
A Study to Evaluate RIST4721 in Palmoplantar Pustulosis (PPP)
- First Posted Date
- 2019-06-17
- Last Posted Date
- 2022-04-05
- Lead Sponsor
- Aristea Therapeutics, Inc.
- Target Recruit Count
- 35
- Registration Number
- NCT03988335
- Locations
- π¨π¦
Brunswick Dermatology Center, Fredericton, New Brunswick, Canada
π©πͺHautarztpraxis Dr. Niesmann & Dr. Othlinghaus, Bochum, Germany
π¨π¦Lynderm Research Inc., Markham, Ontario, Canada
Study to Investigate Safety, Tolerability and Effect of Multiple Dosing With AZD 4721 and/or With AZD 5069
- Conditions
- Chronic Obstructive Pulmonary Disease (COPD).
- Interventions
- First Posted Date
- 2013-10-16
- Last Posted Date
- 2015-06-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 84
- Registration Number
- NCT01962935
- Locations
- π¬π§
Research Site, London, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.